clinical trial · NCT03722407
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
H. Lee Moffitt Cancer Center and Research Institute·phase2·active not recruiting·n = 29
Chronic Myelomonocytic LeukemiaLeukemiaRuxolitinib
brief summary
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
started
Aug 28, 2019
primary completion
Sep 19, 2022
completion
May 1, 2027
last updated
Jul 1, 2026
official title
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol